Growth delay due to insulin-like growth factor I resistance is a rare genetic condition that affects height and growth from early childhood. People with this condition are shorter than peers, and may have delayed bone age and slow growth despite normal or high growth hormone levels. Doctors describe this as the body not responding well to IGF‑I, so growth remains limited over time. It is lifelong, but growth-focused care in childhood and adolescence can help, including recombinant IGF‑1 therapy and nutrition support. Most people with Growth delay due to insulin-like growth factor I resistance have a normal life span, and regular follow-up with pediatric endocrinology is key.
Overview
Growth delay due to insulin-like growth factor i resistanceSymptoms
Growth delay due to insulin-like growth factor I resistance often appears as slow growth and shorter height than peers from early childhood. Infants can have episodes of low blood sugar. Some also experience delayed puberty and smaller hands and feet.
Outlook and prognosis
Most children with growth delay due to insulin-like growth factor I resistance grow more slowly but can gain height and strength with tailored care. Early diagnosis, optimized nutrition, targeted hormone or growth-factor treatments, and regular monitoring often improve growth patterns and long-term health.
Causes and risk factors
Common genetic causes of growth delay due to insulin-like growth factor I resistance involve inherited changes affecting growth hormone–IGF‑1 signaling. Risk factors include family history, parents being related by blood, and ancestry from communities with higher carrier rates.
Genetic influences
Genetics plays a major role in growth delay due to insulin-like growth factor I resistance. Variants in the IGF1, IGF1 receptor, or related pathway genes can reduce the body’s response to IGF-I. Inherited and new (de novo) changes both occur.
Diagnosis
Doctors assess growth charts and clinical features, often with bone age X-rays. Hormone testing (IGF-1/GH patterns) supports the diagnosis. Genetic diagnosis of Growth delay due to insulin-like growth factor i resistance is confirmed by IGF1R testing.
Treatment and drugs
Treatment focuses on improving growth and overall health. Doctors may use growth hormone or IGF‑1 therapy, tailor nutrition, and monitor blood sugar, growth rate, and puberty. Care often includes endocrinology, dietetics, and regular checks to adjust therapy for growth delay due to insulin-like growth factor I resistance.
Symptoms
Day to day, growth delay can look like smaller clothing sizes, shoes that last a long time, and a child who seems younger than classmates. In growth delay due to insulin-like growth factor I resistance, the body doesn’t respond as expected to a key growth signal, so gains in length, height, and head size tend to be slower before and after birth. Early features of growth delay due to insulin-like growth factor I resistance include being small at birth, slow childhood growth, and sometimes a smaller head size. Features vary from person to person and can change over time.
Many babies are smaller than expected for their gestational age, with lower birth weight and length. This can mean tiny clothes fit longer and hospital staff monitor growth closely.
Height and weight may climb more slowly than friends of the same age. In growth delay due to insulin-like growth factor I resistance, growth charts often show a gentle slope rather than steady jumps. Parents may notice clothing sizes change less often.
Children and adults are often shorter than peers. Body proportions are usually balanced, so the whole body is small rather than just the legs or trunk. This pattern fits growth delay due to insulin-like growth factor I resistance.
The head may measure smaller than average for age, known as microcephaly. This can be mild and may not affect day-to-day abilities.
How people usually first notice Growth delay due to insulin-like growth factor i resistance?
Parents and clinicians often first notice growth delay due to insulin-like growth factor I (IGF‑I) resistance when a baby or toddler falls well below expected length/height percentiles despite adequate nutrition and normal thyroid function, and keeps crossing downward on the growth chart over several checkups. In infancy or early childhood, doctors may see a small head size, delayed tooth eruption, or low growth velocity, and lab tests can show low-normal or high IGF‑I that doesn’t match the child’s short stature, suggesting the body isn’t responding to this growth signal. For many families, the first signs of growth delay due to IGF‑I resistance are slow linear growth and shorter height compared with peers, prompting referral to a pediatric endocrinologist for growth hormone–IGF evaluation.
Types of Growth delay due to insulin-like growth factor i resistance
Growth delay due to insulin-like growth factor I resistance can look different from child to child. Some have milder short stature and grow steadily, while others show a marked slowdown and need earlier support. Doctors recognize a few well-established variants tied to how the IGF-I pathway is blocked or how the body handles the hormone, and these variants help explain differences in height, head size, and body proportions. When people ask about the types of this condition, they usually mean variants of the IGF-I pathway—this helps families compare types of Growth delay due to insulin-like growth factor I resistance.
GH receptor defect
This variant reflects an issue with the growth hormone (GH) receptor, so the body can’t make enough IGF-I in response to normal GH. Children often have severe short stature from early life, with normal birth size but slow growth after. Facial features and body proportions can be distinctive, and labs typically show high GH with low IGF-I.
IGF1 gene mutation
Here, the IGF1 gene itself doesn’t work as expected, so IGF-I levels are low or the hormone is not made correctly. Children can have notable growth delay, sometimes with a smaller head size. Hearing or learning differences may occur in some cases.
IGF1R gene mutation
In this type, the IGF-I receptor is less responsive, so IGF-I can be normal or high but signaling is weak. Kids usually have proportionate short stature and may have a smaller head size. Some may also show mild differences in facial features.
Post-receptor signaling
This covers defects in proteins that carry the IGF-I signal inside the cell (downstream of the receptor). Growth can be moderately to severely affected depending on which step is impacted. Lab results may not neatly match other types, making genetic testing important when exploring types of Growth delay due to insulin-like growth factor I resistance.
IGF binding protein
Changes in IGF-binding proteins or the acid-labile subunit can alter how IGF-I is carried in blood, affecting how much reaches tissues. Children may have low total IGF-I but variable “free” IGF-I and a wide range of growth impact. Features can be milder than receptor or IGF1 gene defects, but this varies.
What genetics can tell you about symptoms
Variants in the IGF1R gene can blunt cells’ response to insulin-like growth factor, leading to short stature, slow growth, and delayed puberty despite normal or high IGF-1 levels. Some with PAPP-A2 or ALS (IGFALS) variants show low bioactive IGF-1, thin bones, and low muscle mass.
Causes and risk factors
The main driver is a reduced response to IGF-1, often from changes in the IGF-1 receptor gene (IGF1R) or in its signaling steps. These gene changes can be inherited from a parent or can arise for the first time. Some risks are modifiable (things you can change), others are non-modifiable (things you can’t). Non-modifiable risk factors for growth delay due to insulin-like growth factor i resistance include a family history of short stature, being born small for gestational age, or known IGF1R changes. Modifiable factors that can blunt the IGF-1 pathway and growth include poor nutrition, chronic illness or inflammation, thyroid or liver disease, and long-term steroid use.
Environmental and biological risk factors
When growth is slower than expected because the body does not respond well to insulin-like growth factor I (IGF-1), families often want to know what might raise the chance of this happening. Below are environmental and biological risk factors for growth delay due to insulin-like growth factor I resistance that researchers and clinicians commonly consider. Doctors often group risks into internal (biological) and external (environmental). Understanding these elements can help you and your care team focus on what can be monitored during pregnancy and early life.
Pregnancy at 35 years or older is linked with higher rates of placental stress that can blunt the fetus’s response to growth signals like IGF-1. This may raise the likelihood of growth delay due to insulin-like growth factor I resistance.
High blood pressure disorders in pregnancy can limit placental blood flow. Reduced oxygen and nutrients can dampen how fetal tissues respond to IGF-1.
When the placenta cannot deliver enough oxygen and nutrients, growth signals may not work as well. This can contribute to growth delay due to insulin-like growth factor I resistance.
Twins or higher-order multiples compete for shared placental resources. Limited supply can weaken IGF-1 signaling effects on growth.
Genetic risk factors
Several rare genetic changes can blunt the body’s response to IGF‑I, leading to slow growth that may start before birth and continue through childhood. Some risk factors are inherited through our genes. The best-known genetic causes of growth delay due to insulin-like growth factor i resistance involve the IGF1R gene and proteins that control how much active IGF‑I reaches cells. Genetic testing can clarify the exact cause and guide care and family planning.
IGF1R variants: Changes in one copy of the IGF1R gene can reduce how cells respond to IGF‑I. This autosomal dominant pattern often leads to small size at birth, short stature, and higher‑than‑expected IGF‑I levels. Effects can vary even within the same family.
15q26 deletions: Loss of a chromosome 15 segment that includes IGF1R lowers receptor number and signaling. Babies are often small for gestational age and continue to grow slowly. Other features may appear depending on how much DNA is missing.
PAPP-A2 deficiency: Faults in the PAPP-A2 gene limit release of active IGF‑I from its binding proteins. Blood tests may show high total IGF‑I but low bioactive (free) IGF‑I, a hallmark pattern in growth delay due to insulin-like growth factor i resistance. This condition is inherited in an autosomal recessive way.
IGFALS mutations: Changes in the IGFALS gene reduce the acid‑labile subunit that stabilizes IGF‑I in the bloodstream. This lowers circulating IGF‑I and IGFBP‑3, limiting delivery of IGF‑I to tissues. Growth is often mildly to moderately reduced.
IGFBP3/IGFBP5 variants: Rare variants in IGF‑binding proteins 3 or 5 can disturb IGF‑I transport and access to tissues. Lab results can be atypical, and height effects range from mild to significant. These changes are uncommon but part of the IGF pathway.
De novo changes: Some IGF1R changes arise for the first time in a child without being inherited. Parents may be of average height, and recurrence risk is usually low. Genetic counseling can help estimate future pregnancy risks.
Family history: A parent with short stature and an IGF1R variant may pass it on in an autosomal dominant pattern. In growth delay due to insulin-like growth factor i resistance, severity can differ from parent to child. Testing relatives can clarify who else may be affected.
Consanguinity: When parents are closely related, the chance of autosomal recessive conditions like PAPP‑A2 or IGFALS deficiency is higher. This can increase risk for growth delay due to insulin-like growth factor i resistance caused by those genes. Carrier testing can help families understand their risks.
Lifestyle risk factors
Lifestyle habits do not cause this condition, but they can influence growth potential, body composition, bone strength, and day‑to‑day functioning. Thoughtful routines can help reduce complications like excess body fat, low bone density, and deconditioning that may accompany IGF‑1 pathway resistance. Here are lifestyle risk factors for Growth delay due to insulin-like growth factor i resistance to consider when planning care.
Highly processed, sugar‑dense foods promote fat gain that can further impair mobility and strain joints in IGF‑1 resistance. Emphasizing whole foods, fiber, and balanced meals supports healthier body composition and steady energy.
Inadequate protein can limit linear growth and muscle development when the IGF‑1 pathway is less efficient. Include lean protein at each meal to meet growth and maintenance needs.
Low calcium or vitamin D weakens bone mineralization, increasing fracture risk in shorter, smaller bones. Consistent intake (foods or supplements as advised) supports bone density across childhood and adulthood.
Regular weight‑bearing and resistance exercise builds muscle and bone despite IGF‑1 resistance. It also improves insulin sensitivity and helps counter excess adiposity that can accumulate in this condition.
Risk prevention
You can’t fully prevent Growth delay due to insulin-like growth factor i resistance because it’s most often genetic, but you can lower the chance of complications and support healthy development. Prevention can mean both medical steps, like vaccines, and lifestyle steps, like exercise. Spotting early symptoms of Growth delay due to insulin-like growth factor i resistance—such as poor length gain in infancy—allows earlier specialist care. Genetic counseling can also help families understand inheritance and future pregnancy options.
Learn how the condition runs in families and your chances in future pregnancies. Discuss carrier testing, prenatal testing, or IVF with embryo testing when appropriate.
Track length/height, weight, and head growth closely in infancy and childhood. If growth patterns suggest IGF-1 resistance, an early endocrine referral can speed diagnosis and treatment.
Work with a pediatric or adult endocrinologist to create a tailored plan. Growth hormone alone usually doesn’t help in IGF-1 resistance, but IGF-1–based therapy may.
If prescribed mecasermin (IGF-1), give doses with meals to reduce low blood sugar risk. Learn signs of hypoglycemia and have a plan for quick glucose.
Transmission
Growth delay due to insulin-like growth factor i resistance is not contagious; it can’t be passed through touch, air, food, or blood. It happens because of a change in a growth-related gene—often one that helps cells “hear” the IGF‑1 signal—so the body doesn’t respond to IGF‑1 as expected.
In many families, this follows an autosomal dominant pattern, meaning one changed copy of the gene from an affected parent can be enough to pass it on; in other cases, the change is new in the child (a de novo variant) with no prior family history. If you’re wondering how growth delay due to insulin-like growth factor i resistance is inherited, a genetic counselor or clinical geneticist can explain your family’s chances and discuss options for future pregnancies.
When to test your genes
Test your genes if a child has slow growth with low IGF‑1 activity despite normal or high levels, especially with family history of short stature or consanguinity. Consider testing before starting growth hormone or IGF‑1 therapy to guide treatment and dosing. Re‑test isn’t routine unless new symptoms or research emerge.
Diagnosis
For many, the first step comes when everyday activities start feeling harder, like noticing your child is much shorter than classmates or outgrows shoe sizes slowly. Doctors usually begin with a careful growth review and exam, then add targeted tests to see where the growth signal may be getting blocked. The genetic diagnosis of growth delay due to insulin-like growth factor I resistance typically combines clinical clues with hormone measurements and, when needed, DNA testing to confirm the cause.
The doctor reviews height, weight, head size, and body proportions over time. They look for patterns in growth that suggest a problem with the growth hormone–IGF pathway.
A detailed family and health history can help identify inherited patterns and early clues. Information on prenatal growth, birth weight/length, and parents’ heights provides important context.
Serial measurements are plotted on standardized charts to track velocity over months and years. Calculating a target height from parents helps judge whether growth is below the expected range.
Thyroid function, celiac screening, blood counts, and kidney and liver tests help rule out common medical causes of slow growth. This narrows the focus to hormonal and genetic explanations.
Stages of Growth delay due to insulin-like growth factor i resistance
Growth delay due to insulin-like growth factor i resistance does not have defined progression stages. It usually presents as a steady pattern of poor growth rather than stepwise worsening, so doctors track height and weight over time instead of labeling stages; early symptoms of growth delay due to insulin-like growth factor i resistance often show up as falling behind peers on the growth chart. Diagnosis relies on growth measurements, a bone age X-ray, and blood tests looking at IGF-related levels and other hormones, often alongside a review of family heights and birth history. Different tests may be suggested to help confirm the cause, including genetic testing for changes in the IGF1 receptor, and ongoing monitoring focuses on growth velocity and overall development.
Outlook and prognosis
Many people ask, “What does this mean for my future?”, especially when growth delays are linked to insulin-like growth factor I (IGF‑1) resistance. Day to day, this condition mostly affects height and body proportions, and sometimes energy and muscle mass. The outlook is not the same for everyone, but early diagnosis and a tailored plan can help children reach better growth potential and support healthy development.
Prognosis refers to how a condition tends to change or stabilize over time. In IGF‑1 resistance, growth plates often respond less to usual signals, so untreated short stature usually persists into adulthood. That said, targeted therapies—such as recombinant IGF‑1 in eligible children—can improve height velocity, especially when started young. Early symptoms of growth delay due to insulin-like growth factor I resistance may also include low blood sugar in infancy; when recognized and managed early, long-term cognitive and metabolic outcomes are generally good.
Everyone’s journey looks a little different. Some people notice mainly short stature with otherwise typical health, while for others there may be added challenges like delayed puberty or reduced bone density that call for ongoing monitoring. Life expectancy is typically normal when hypoglycemia and other complications are well controlled; increased mortality is not expected in most cases with appropriate care. Keep regular appointments—small adjustments can improve long-term health. Talk with your doctor about what your personal outlook might look like, including whether genetic testing could clarify the specific cause of IGF‑1 resistance and guide treatment timing.
Long-term effects
Growth delay due to insulin-like growth factor I resistance often leads to lifelong short stature and a slower growth pattern from early childhood onward. Long-term effects vary widely, so height, body build, and health markers can look quite different from one person to another. Many grow and develop at their own pace, with puberty and bone changes sometimes arriving later than peers. Over time, doctors track growth, puberty, and bone health to understand each person’s outlook.
Most people reach a final height well below family averages but with proportionate body build. This reflects the long-standing effect of IGF-I resistance on bone growth.
Early signs of growth delay due to insulin-like growth factor I resistance include a slow climb on the height curve and short stature compared with classmates. Growth usually continues steadily but at a reduced pace.
Puberty often starts later than average, with slower progression through the stages. Adult sexual development is typically achieved, though timing can vary.
Lower bone mineral density can develop, raising lifetime fracture risk. Doctors often describe these as long-term effects or chronic outcomes.
How is it to live with Growth delay due to insulin-like growth factor i resistance?
Living with growth delay due to insulin-like growth factor I resistance often means shorter stature and slower growth compared with peers, with frequent clinic visits to track height, adjust care, and address nutrition and bone health. Day to day, reaching high shelves, finding well-fitting clothes, or keeping up in sports may take extra planning, while school or work settings sometimes require simple accommodations like step stools or seating adjustments. Families and friends play a key role—offering practical help, advocating in appointments, and reinforcing confidence when comments or comparisons sting. Many find that consistent medical follow‑up, clear communication at school or work, and connecting with supportive communities make a noticeable difference in comfort and independence.
Treatment and drugs
Treatment for growth delay due to insulin-like growth factor I (IGF-I) resistance focuses on helping children grow, supporting overall health, and monitoring for related issues over time. Standard growth hormone usually doesn’t work well in true IGF-I resistance, so doctors may consider recombinant human IGF-1 (mecasermin) given by injection, started at low doses and carefully adjusted to reduce side effects like low blood sugar; a doctor may adjust your dose to balance benefits and side effects. Careful meal timing around injections, nutrition support, and management of low blood sugar with quick sources of glucose are important parts of day-to-day care. Regular follow-up typically includes tracking height and weight, checking vision and hearing, watching for scoliosis, and coordinating care with pediatric endocrinology, nutrition, and sometimes genetics. Although living with growth delay due to IGF-I resistance can feel overwhelming, many people manage their symptoms and live fulfilling lives.
Non-drug treatment
Growth delay due to insulin-like growth factor i resistance can affect height, energy, and day-to-day activities over time. Alongside medicines, non-drug therapies can strengthen growth, learning, and overall well-being. The goal is to support steady development, prevent complications, and help children and families feel confident with daily routines. Needs vary by age and subtype, so plans are tailored and adjusted over time.
A balanced diet with enough protein, healthy fats, and complex carbs supports growth and steady energy. Calcium- and vitamin D–rich foods help bones and teeth stay strong.
Small, regular meals and snacks can reduce dips in blood sugar and fatigue. Keeping a predictable eating schedule often helps children stay active and focused.
Regular checks of height, weight, and head growth help spot changes early. Tracking early symptoms of growth delay due to insulin-like growth factor i resistance can guide timely referrals and therapies.
Guided exercises improve strength, balance, and coordination. Therapy can also fine-tune posture and movement patterns for safer play and sports.
Your genes may have an impact on how drugs work for you
Genes can change how your body responds to growth hormone and IGF‑1 therapies, affecting how well they work, the dose you need, and side effects. Testing key variants can guide choices, aiming for safer, more effective treatment for growth delay.
Pharmacological treatments
Treatment focuses on helping children grow and preventing low blood sugar while therapy is underway. Mecasermin (recombinant IGF‑1) is the main medicine when the body can’t use growth signals properly, and it’s typically started in childhood. Treatment works best when started before puberty, even if early symptoms of growth delay due to insulin-like growth factor I resistance were easy to miss. Dosing may be increased or lowered gradually to balance growth benefits with side effects.
Mecasermin can improve height gains by replacing IGF‑1 activity, especially when started before puberty. It’s injected with meals or a snack to reduce the risk of low blood sugar. Side effects can include hypoglycemia and enlarged tonsils, so regular monitoring is important.
Somatropin may be tried in selected cases with partial IGF‑1 resistance (for example, some IGF1R changes), but height gains are often modest. It is generally not helpful when the growth hormone receptor is absent or nonworking. Not everyone responds to the same medication in the same way.
Glucagon injection or nasal spray is used for severe low blood sugar that can occur with mecasermin. Caregivers are taught when and how to give it and to call emergency services afterward. Keeping a kit at home and school helps ensure quick treatment.
Genetic influences
Genetic changes are a key reason the body doesn’t respond as it should to insulin‑like growth factor‑1 (IGF‑1). Most often, this involves a change in a gene called IGF1R, which makes the IGF‑1 receptor; when the receptor doesn’t work well, growth signals are weaker. These changes can be inherited from a parent with short stature or can happen for the first time in a child. Even with the same gene change, people can show very different degrees of small size at birth and later height. One altered copy is often enough to cause Growth delay due to insulin-like growth factor i resistance, and the specific change may be a tiny difference in the gene or a small missing piece of chromosome that includes the gene. Because the growth signal is blunted from early development, early symptoms of growth delay due to insulin-like growth factor I resistance may be noticed before or soon after birth. Genetic testing can look for IGF1R changes and related chromosome alterations, helping confirm the cause, clarify inheritance, and guide who else in the family might consider testing.
Is Growth delay due to insulin-like growth factor i resistance genetic?
Genetics plays a major role in growth delay due to insulin-like growth factor I resistance. Variants in the IGF1, IGF1 receptor, or related pathway genes can reduce the body’s response to IGF-I. Inherited and new (de novo) changes both occur.
Pharmacogenetics—how genetics influence drug effects
Which treatment helps most depends on where the resistance sits in the body’s growth pathway. In growth delay due to insulin-like growth factor I (IGF-1) resistance, changes in genes that affect the growth hormone signal, IGF-1 itself, its binding proteins, or the IGF-1 receptor can determine whether growth hormone shots will help or whether IGF-1 replacement (mecasermin) is the better choice. People with growth hormone receptor defects usually don’t respond to growth hormone, but many can grow with IGF-1 therapy, with dose and meal timing adjusted to lower the risk of low blood sugar. When the IGF-1 receptor is affected, response to IGF-1 can be limited, so care often emphasizes realistic goals, nutrition, and close growth tracking rather than expecting large height changes. Genetic testing can sometimes identify how your body is likely to respond, helping doctors choose the medicine and dose and reduce unnecessary side effects. These results are combined with age, nutrition, and other health factors to fine-tune the best treatment options for growth delay due to insulin-like growth factor I resistance.
Interactions with other conditions
Other health issues can add to the growth challenges and day‑to‑day energy needs in growth delay due to insulin-like growth factor I resistance. Thyroid disorders, celiac disease, inflammatory bowel disease, and chronic kidney or liver disease can all reduce growth further by disrupting hormones or nutrition, so teams often screen and treat these alongside the growth problem. Doctors call it a “comorbidity” when two conditions occur together. Because early symptoms of growth delay due to insulin-like growth factor I resistance can resemble thyroid problems or malabsorption, differentiating them matters—treating those conditions may improve growth potential even when IGF‑I resistance remains. Blood sugar issues also intersect: some children have low blood sugar, and if diabetes or diabetes medications are in the picture, IGF‑I treatment may require closer meal planning and glucose monitoring to avoid hypoglycemia. Long‑term steroid use for asthma or autoimmune conditions can slow growth as well, so clinicians try to minimize doses and protect bone health when possible. Talk with your doctor about how your conditions may influence each other, especially when multiple specialists or medications are involved.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described children who stayed much smaller than their peers despite eating well and seeming otherwise healthy. Families told stories of siblings who were short across generations, and some remembered relatives who never “caught up” in height even through adolescence. In daily life, this could look like a child still wearing much younger clothing sizes, or being mistaken for a younger grade at school, while keeping up mentally and socially.
First described in the medical literature as a form of growth failure that didn’t improve with standard growth hormone treatment, this pattern puzzled clinicians for decades. Early reports focused on careful measurements: birth length, growth charts, and bone age on X‑rays. Doctors noticed that many children showed normal or high levels of growth hormone, yet their bodies didn’t translate those signals into growth. As medical science evolved, researchers began to study the body’s response to insulin‑like growth factor, a key messenger that sits “downstream” from growth hormone.
From early theories to modern research, the story of growth delay due to insulin-like growth factor I resistance moved from bedside observation to lab discovery. By the late 20th century, advances in blood testing and cell studies showed that some children made IGF‑I but their tissues didn’t respond to it well, similar to how a dimmer switch can blunt a light’s brightness even when the power is on. In other cases, the body made too little IGF‑I in the first place. This helped explain why growth hormone shots alone often didn’t help.
In recent decades, knowledge has built on a long tradition of observation. Scientists linked certain gene changes to the IGF‑I pathway and mapped how these changes could affect receptors, binding proteins, and signaling steps within cells. This shifted thinking from a single diagnosis to a spectrum: some people have mild resistance and grow slowly but steadily; others have marked short stature from early childhood. Clinicians also learned that features can vary—some children have small head size at birth, some have delayed bone age, while others mainly show short stature without other findings.
Understanding this history shaped care. Awareness that the problem lies in the IGF‑I pathway opened the door to targeted treatments for selected children and clearer counseling for families who had long noticed similar patterns. Looking back helps explain why early treatments sometimes failed and why testing now focuses not just on hormone levels, but on how the body responds to them. As research continues, the path from careful growth charts to precise molecular insight shows how sustained observation and genetics together refined what we now call growth delay due to insulin-like growth factor I resistance.